In recent years, many departments of the state are continuously introducing a series of favorable policies such as optimizing the review and approval system, launching "major new drug creation", and simplifying clinical trial approval procedures to promote the upgrading and transformation of the domestic pharmaceutical industry from generic drugs to innovative drugs, and encourage more new drugs with clinical value to quickly enter the clinical stage
.
At present, driven by a series of favorable policies, new drugs are continuously being approved
in clinical trials.
R&D and innovation of pharmaceutical companies have become a boom, forcing the pharmaceutical equipment industry to accelerate its rise (Image source: Pharma.
com)
For example, on November 2, Ascletis announced that it had submitted a new drug clinical trial (IND) application for the protease (3CLpro) inhibitor ASC11 to
the US Food and Drug Administration (FDA).
It is understood that ASC11 is an oral small molecule drug
candidate independently developed by using a variety of proprietary technologies including molecular simulation docking.
To date, Ascletis has filed a number of patent applications
worldwide for ASC11 and related compounds and their use in the treatment of viral diseases.
In addition, Ascletis has completed all ASC11 clinical clearance studies, including GLP-compliant toxicological studies
in rats and dogs.
On the same day, Acro Biotech announced that the clinical trial application of the new PD-L1/4-1BB bispecific antibody "HK010 injection" with independent intellectual property rights has been approved by the State Food and Drug Administration and is intended to be used for the treatment of advanced malignant tumors
.
Anko Biotech said that it will accelerate the clinical trial
of HK010 injection as soon as possible under the leadership of the Affiliated Cancer Hospital of Fudan University.
.
.
.
.
.
.
In addition to the continuous clinical approval of new drugs, according to the statistics of the State Food and Drug Administration and the Drug Evaluation Center of the State Medical Products Administration, as of October 5, 14 blockbuster innovative drugs have been approved for marketing
in 2022.
Among them, a number of innovative drugs from Chinese pharmaceutical companies have been approved, including Akeso's PD-1/CTLA-4 bispecific antibody cardonilimab (AK104), Hansen Pharmaceutical's CD19 monoclonal antibody inalizumab injection, CSPC's PI3Kδ/γ inhibitor duvelisel capsules, etc
On the whole, with the increase of policies, the domestic innovative drug industry is accelerating its development, among which high-quality innovative drug companies are also ushering in more opportunities
.
It is worth noting that new demand gives birth to new impetus
.
Industry insiders believe that pharmaceutical equipment, as the "mother machine" of pharmaceutical production, its industrial development level is closely related to the pharmaceutical level, so it should follow up the new requirements and new requirements of the pharmaceutical industry, strengthen R&D and innovation, constantly update and upgrade, and solve the pain points and difficulties in the development process of pharmaceutical enterprises, in order to inject "new vitality"
into the innovation and development of pharmaceutical enterprises.
In recent years, with the rapid development of the pharmaceutical industry and the acceleration of innovation and upgrading, as well as the continuous breakthrough of emerging biotechnology in China, the promotion of emerging industries such as biomedicine and health industry, in fact, the market demand for high-end pharmaceutical equipment is expanding
.
In this regard, the industry believes that the upstream pharmaceutical equipment industry also needs to innovate and develop in the high-end direction of intelligence, informatization, integration and greening, in order to better meet the needs of high-quality and sustainable development of
the modern pharmaceutical industry.
In fact, Chutian Technology, Dongfulong, Xinhua Medical, Canaan Technology, Qianshan Yao Machine, Weilong Technology, etc.
have already carried out active actions
in the above fields.
For example, in terms of intelligence, they are developing intelligent pharmaceutical equipment and building intelligent factories
.
Among them, in the second half of 2021, Canaan Technology's intelligent medical equipment manufacturing project with a total investment of 1 billion yuan is planned to be completed in 2023, and three standardized production workshops have all been topped out
.
It is worth mentioning that talent is the source of enterprise innovation and the core element of
enterprise innovation.
Therefore, at present, many pharmaceutical equipment enterprises are also talent-oriented, and are accelerating the construction of high-quality scientific and technological talents to build hard power
.
For example, the 2022 half-year report of Chutian Technology shows that the number of technical research and development personnel in the first half of the year increased by more than 650 compared with the same period, and the introduction of technical backbone talents is the focus, and the number of technical research and development personnel of the group during the reporting period was nearly 2,000
.
In addition, from 2020 to 2021, the number of R&D personnel has also increased from 396 (14.
88%) to 677 (18.
44%)
.
In general, the continuous introduction of a series of favorable innovation policies in the pharmaceutical industry is driving pharmaceutical companies to accelerate the improvement and innovation
of dosage forms.
In this context, pharmaceutical companies will be forced to continuously update and upgrade their equipment to better meet the new needs
of pharmaceuticals.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
